About the Report
Blood collection tubes are essential diagnostic products used for laboratory biopsy testing. Liquid biopsy is the procedure of separation of circulating DNA (ct) DNA, which is the DNA obtained from tumours, from a patient's plasma or serum. The discovery of DNA variation in tumour tissues is important in many diagnostic programs. Development of critical techniques has allowed for the detection of tumour-specific aberrations in circulating tumour (ct) DNA.
According to Fact.MR’s analysis, the blood collection tubes for liquid biopsy market will expand at an impressive CAGR of around 12% from 2020 to 2030.
Blood collection tubes for liquid biopsy provide accuracy and precision, safety, speed, and ease-of-use in the diagnostic process. In its revised study, Fact.MR offers insights about key factors driving demand across regions. This latest report tracks global sales of blood collection tubes for liquid biopsy in 25 high-growth markets, where major traction is being witnessed in North America, followed by Europe. This edition (2020-2030) brings readers up-to-date with key developments in the market, providing analysis on how manufacturers and other stakeholders are reacting to change.
Future Outlook Much Brighter than Previous Years
Technological advances have increased the diversity of blood collection tubes for liquid biopsy applications. Liquid biopsy analysis has evolved as a promising tool for early detection of tumours, providing a more complete picture of the tumour genome, as well as monitoring tumour emergence during disease.
Development of critical techniques has allowed for the detection of tumour-specific aberrations in ctDNA. ctDNA can be analysed to investigate or monitor pathological changes in tumour genome — from chromosomal aberrations such as microsatellite modification, rearrangement, amplification, and copy number variations. Also, CTCs can be used to predict breast cancer, as well as several strong cancer cells such as prostate, ovarian, and colorectal cancer.
Initiatives by governments for better regulatory measures and investments in R&D and healthcare are expected to boost demand, owing to the development of better and non-invasive techniques to detect tumour-specific aberrations, leading to market growth over the coming years. Use of cellular DNA from plasma emerges as an important small invasive tool for clinical diagnosis. Especially in paediatric oncology, minimal fluid biopsy attacks show a good way to identify the genomic features of a DNA tumour. Continuous investments in product development will lead to commercialization of blood collection tubes for liquid biopsy with the ability to be incorporated in applications such as NGS, PCR, and DNA methylation assays.
Increasing advancements in technology, product launches, mergers & acquisitions, and strategic collaborations formed by leading market players will lead to higher adoption of blood collection tubes for liquid biopsy, globally, and will further bring more product developments to the market. For instance, in January 2020, Biodesix, Inc. and Streck, Inc., announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.
Will Need for Enhanced Precision & Accuracy for Blood Collection Techniques Boost Demand?
Innovative techniques and products are constantly being developed for diagnosis to increase patient safety, which is an important factor driving market growth. New systems have several advanced features such as analysis of cell-free DNA (ccfDNA) as a sensitive biomarker for cancer diagnosis. Biomarkers such as DNA, RNA, proteins, or a cell play an important role in the development of translational medicine, which facilitates the translation of basic research into medical advances. These value additions would help increase adoption by end users. ctDNA in whole blood indicates tumour genome heterogeneity, including primary tumour and distant metastasis. Also, CTCs can be used to predict breast cancer, as well as several strong cancer cells such as prostate, ovarian, and black cancer.
Advanced diagnostic devices with high precision and accuracy are gaining popularity in the IVD and research application segment. Along with that, regulatory bodies are continuously trying to create favourable scenarios for the development and commercialization of blood collection tubes for liquid biopsy, owing to producing high-quality diagnostic assay methods for cancers and other chronic diseases. Increasing geriatric population and unhealthy lifestyles have led to rising incidence of chronic diseases, which is expected to significantly boost demand for blood collection tubes for liquid biopsy.
Why are Genetic Diagnostic Labs leading the Market?
There has been significant healthcare expenditure towards developing and improvising infrastructure in developing regions. As a result, there are a rising number of pharmaceutical and biotechnology companies across the globe, with an increasing rate of adoption of highly sensitive techniques for detection of tumour-specific aberrations DNA. Clinical innovations, financial incentives, and improved healthcare infrastructure will increase the growth of genetic diagnostic labs for blood collection tubes for liquid biopsy with precise and non-invasive methods of diagnostic assays.
What are the Key Challenges Faced by Manufacturers?
Lack of skilled professionals required to operate instruments is a major factor that can restrain the growth of the market for blood collection tubes for liquid biopsy. Blood Collection is a sensitive technique, and negligence in operation or lack of skill can ruin the process. Such techniques require highly qualified and trained professionals who understand the technology and mechanism.
Another restraint is early expiration dates of glass and plastic blood collection tubes, which is generally limited by the shelf life of additives, because vacuum and water vapour losses are minimal over time.
Why is the U.S. a Leading Market for Blood Collection Tubes for Liquid Biopsy?
Fact.MR has projected the U.S. to remain the most lucrative market throughout the forecast period. One of the key factors supporting market expansion is advanced healthcare infrastructure in the U.S., making it a lucrative market for blood collection tubes for liquid biopsy.
According to the American Cancer Society, prostate, lung and bronchus, and colorectal cancers account for 42% of all cases in men. Whereas, breast, lung, and colorectal cancers account for 30% of all cancers in women. As per the National Cancer Institute, cancer incidence is 442.4 per 100,000 men and women per year, with a mortality rate of 158.3 per 100,000. This high rate of cancer in the U.S. is complementing demand, and the market is expected to expand at significant CAGR of over 9% during the forecast period.
What is the Market Scope in Germany for Blood Collection Tubes for Liquid Biopsy?
Germany is one of the largest countries in Europe with a cancer incidence of 313.1 per 100,000 people. The most common cancers in Germany are breast, prostate, colorectal, lung, and bladder. These five types accounted for about 57% of all new cancer cases in Germany in 2012. In Germany, it is estimated that, 51% of men and 43% of women will develop cancer during their lifetime.
An organization such as the German National Cancer Plan, the Nationaler Krebsplan, was launched in 2008 by the federal health department, and was established in partnership with the German Cancer Society (Deutsche Krebsgesellschaft), German Cancer Aid (Deutsche Krebshilfe), and the Association of German Inflammatory Centres. The program includes four broad areas of assessment; improving oncological care facilities and quality assurance; to ensure that cancer treatment is effective, and developing a more patient-centred approach. The Krebsfrüherkennungs- und -registergesetz (KFRG), which came into effect in April 2013, and proved to be a milestone in the implementation of this program, which stated the law of early detection of cancer.
The stage in which a person is diagnosed has a significant impact on the challenges they face after a phase of intensive treatment. Thus, Blood Collection Tubes For Liquid Biopsy help support this plan of the organization to early and precisely detect cancer for its prompt treatment, thereby increasing the survival rate of cancer patients. Also, cancer cases are expected to increase by 24% by 2035, making it the leading cause of death in the EU.
Why is France a Lucrative Market for Blood Collection Tubes for Liquid Biopsy?
France is another European country facing surging cases of cancer. Prostate, breast, lung, and colorectal cancer account for more than 47% of all cases. France has the largest population of prostate cancer, with more than 66 thousand new cases detected in 2020. Public health policies are actively involved in aiding cancer prevention and detection plans in France. The French National Cancer Institute is a health and science agency dedicated to cancer. The Institute covers the whole spectrum of the fight against cancer, with plans to detect cancer at the initial stage, to plan better and sustainable treatment for patients.
Why is Demand for Blood Collection Tubes Booming in China?
There has been significant rise in the number of domestic manufacturers and distributors in past few years in China. According to a report on cancer statistics in China, along with the GLOBCAN, there were 4.3 million new cancer cases and 2.9 million deaths in China in 2018. China has a higher mortality rate due to cancer as compared to countries such as the U.S. and U.K. Rising geriatric population and chronic diseases in China are expected to boost the growth of manufacturers in the country.
How is India Faring in the Blood Collection Tubes for Liquid Biopsy Market?
The Indian Council of Medical Research (ICMR) has predicted that by the year 2020, India will see more than 1.7 million new cancer cases, and more than 880,000 Indians will die as a result. Unfortunately, most patients come to know about their cancer at an advanced stage of the disease. The need of the hour is to have better and efficient detection techniques. Late detection is mainly due to shortage of diagnostic centres at primary levels.
Among females, breast cancer is rising, with more than 21% among all cancer cases. While among males, mouth and lung cancer are the highest with 18.3% of all cancers. India is witnessing a high rate of cancer-related mortality due to the unavailability of precise diagnosis, and as such, lack of precise treatment. This means that there is huge scope for blood collection tubes for liquid biopsy manufacturers in the country.
Avail customized purchase options for your needs
Why are ccfDNA Isolation Kits Highly Sought-after?
ccfDNA isolation kits are projected to account for approximately 29% of the global share among product types through the forecast period. This is due to the high sensitivity and high isolation efficiency provided by these kits, which is vital for successful DNA analysis. The analysis of ccfDNA as a sensitive biomarker for cancer diagnosis and monitoring has resulted in the need for efficient and standardized ccfDNA isolation.
Which Material is Most Popular for Blood Collection Tubes for Liquid Biopsy?
Plastics are anticipated to dominate blood collection tubes for liquid biopsy due to their longer shelf life. Plastics are anticipated to have a market share of around 57% market revenue. However, glass is expected to progress at a significant CAGR of 10% during the forecasted period.
Why Does the IVD Segment Hold the Highest Revenue Share among Applications?
Revenue from contract manufacturing organizations is expected to increase at a CAGR of more than 11% over the forecasted period. Increasing cancer population will lead to growth of the IVD segment for efficient diagnosis and treatment, boosting demand for blood collection tubes for liquid biopsy during the forecast period.
Why are Genetic Diagnostic Labs the Largest End Users of Blood Collection Tubes for Liquid Biopsy?
Genetic diagnostic labs hold the largest market share, and is expected to increase at a CAGR of more than 8% during the forecasted period. Growing geriatric population and cancer-related mortality will allow increased use of blood collection tubes for liquid biopsy in genetic diagnostic labs over the coming years.
Leading market players are focused on expanding their product portfolios and global footprint, along with attracting investments through mergers, acquisitions, and strategic collaborations. For instance, in January 2020, Biodesix, Inc. and Streck, Inc., announced a Regulatory Cooperation Agreement that will further enable both companies in their pursuit of FDA approval for diagnostic testing services and specimen collection products.
An Adaptive Approach to Modern-day Research Needs
Scope of Report
Historical Data Available for
|USD Million for Value and Volume in Units|
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
|Customization & Pricing||
Available upon Request
Key Segments of the Blood Collection Tubes for Liquid Biopsy Market
Market by Category
- ccfDNA Tubes
- ccfDNA Isolation Kits
- cfRNA Tubes
- ccfRNA Isolation Kits
- CTC Tubes
- gDNA Tubes
- gDNA Isolation Kits
- Intracellular RNA Tubes
- Intracellular RNA Kits
- R&D centres
- Genetic Diagnostic Labs
- Conventional Diagnostic Centres
- North America
- Latin America
- East Asia
- South Asia
- FAQs -
North America has the highest market share for blood collection tubes for liquid biopsy. Increasing cancer patient pool along with a large number of R&D centres is creating high growth opportunities for the years ahead.
ccfDNA isolation kits are expected to be the most lucrative among the products, with increasing demand for highly sensitive and high-precision diagnostic techniques. The segment is expected to continue to expand at a CAGR of more than 10%.
Some of the leading companies in this landscape are Roche, Streck, Preanalytix, Norgen Biotek, Biocept, Biomatrica, and INVITEK MOLECULAR GMBH (NUVISAN GmbH/STRATEC GROUP).
Plastics are anticipated to dominate manufacturing of blood collection tubes for liquid biopsy, due to their longer shelf life.
IVD is expected to dominate the market over the forecast period, generating a revenue of 54.3 Mn by 2030. On the other hand, research will experience significant growth at a CAGR of approximately 13% through 2030.
Genetic diagnostic labs are expected to dominate the market over the forecast period.
Need an Exclusive Report for your Unique Requirement?
- Related Reports -
Medical Radiation Detection, Monitoring and Safety Market to expand at steady CAGR of 6% and the mar...
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.